EpiBiologics

EpiBiologics is a San Mateo biotech building bispecific antibodies that grab disease-driving proteins on the outside of cells and drag them into the trash. Its EpiTAC platform - spun out of Jim Wells' lab at UCSF - taps a library of more than 270 internalizing receptors so degradation happens in the right tissue and nowhere else. With $280M raised across Seed, Series A and a 2026 Series B led by GV and Johnson & Johnson, the company has pushed its lead EGFR degrader, EPI-326, into a Phase 1 trial for lung and head-and-neck cancers.